Turing Pharmaceuticals, the company that last month raised the price of the decades-old drug Daraprim from $13.50 a pill to $750, now has a competitor.

Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company based in San Diego, announced today that it has made an alternative to Daraprim that costs about a buck a pill—or $99 for a 100-pill supply.

“While we respect Turing's right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim,” Mark L. Baum, CEO of Imprimis, said in a news release.

The alternative is not exactly the same as Daraprim, but it’s close. Daraprim’s active ingredient is pyrimethamine, which has been available since 1953 for the treatment of parasitic diseases (namely malaria and toxoplasmosis). Imprimis’ alternative also contains pyrimethamine as well as leucovorin, which the company said helps to reverse pyrimethamine’s negative effects on bone marrow.

Until now, Turing was the sole source of a pyrimethamine-based drug, which is often prescribed to patients with compromised immune systems such as those suffering from AIDS and cancer.

The price increase of Daraprim, announced last month, sparked widespread outrage against the company and its founder and chief executive, Martin Shkreli. The move by Imprimis is in direct response to those events, and the company said it plans to produce more cheap alternative drugs. In the news release, the company announced the start of a new program called Imprimis Cares, which will ensure affordable versions of the 7,800 generic FDA-approved drugs.